Delivery Order SPE2DB25D3017-SPE2DB25FVKGB
- Not listed
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $2,289.71 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $3,682.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 22, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order executes under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 29, 2025. This non-competitive delivery order represents a firm fixed price transaction and is classified as a child contract under AmerisourceBergen's larger contract vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,167.15 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply agreements with the agency. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $3,734.26 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), carries a firm fixed price structure and is scheduled for completion by August 15, 2025. The product will be delivered to the company's facilities in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,115.57, with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger federal contract vehicle. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,853.05 on August 7, 2025, for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. As a child order under a...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKGBDelivery Order
The Defense Logistics Agency awarded a $3,834.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 18, 2025. This non-set-aside contract was competitively awarded on August 15, 2025, with performance occurring at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, reflecting the company's role as a critical distributor of medications to military and veteran healthcare systems. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contracting activity demonstrates its capability to fulfill complex medical procurement requirements through open competition, with delivery orders ranging significantly in value across multiple therapeutic domains including diabetes management products such as this insulin delivery.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/15/25 |